U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H18N4O2
Molecular Weight 298.3403
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIRIBEDIL

SMILES

c1cnc(nc1)N2CCN(CC2)Cc3ccc4c(c3)OCO4

InChI

InChIKey=OQDPVLVUJFGPGQ-UHFFFAOYSA-N
InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2

HIDE SMILES / InChI

Molecular Formula C16H18N4O2
Molecular Weight 298.3403
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Piribedil is an antiparkinsonian agent which acts as D2 and D3 receptor agonist. In European countries and worldwide it is used as a monotherapy or in combination with dopatherapy for treatment of Parkinson's disease, cognitive impairment and obliterating arteriopathy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35462
Gene ID: 1814.0
Gene Symbol: DRD3
Target Organism: Homo sapiens (Human)
Target ID: P14416
Gene ID: 1813.0
Gene Symbol: DRD2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TRIVASTAL

Approved Use

Adjunctive treatment of intermittent claudication in chronic obliterating arteriopathies of the lower limbs (in stage 2).
Palliative
TRIVASTAL

Approved Use

Adjunctive symptomatic treatment of chronic pathological cognitive and neurosensorial deficit in elderly subjects (excluding Alzheimer's disease and other dementia).
Primary
TRIVASTAL

Approved Use

Treatment of Parkinson's disease: either as monotherapy (treatment of forms with predominant tremor), or in association with dopatherapy from the outset, or secondarily, particularly in forms with tremor.
PubMed

PubMed

TitleDatePubMed
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
1976 May
A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.
1977 Jun
Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495).
1978
Pharmacological treatment for aphasia following stroke.
2001
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
2001 Jun
Piribedil for restless legs syndrome: a pilot study.
2001 May
[Use of dopamine analogs in Parkinson's disease treatment].
2002
[Use of dopamine agonists in the treatment of Parkinson's disease].
2002
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
2002
Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers.
2002 Feb
Gateways to clinical trials.
2002 Jul-Aug
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
2003
Quantitative determination of some pharmaceutical piperazine derivatives through complexation with iron(III) chloride.
2003 Aug
Piribedil-induced sleep attacks in Parkinson's disease.
2003 Feb
Age-related mild cognitive deficit: a ready-to-use concept?
2003 Mar
[Treatment of Parkinson's disease: use of piribedil].
2004
[The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
2004 Apr 16-30
Acute treatment of migraine. Breaking the paradigm of monotherapy.
2004 Jan 28
Determination of piribedil in pharmaceutical formulations by micellar electrokinetic capillary chromatography.
2004 May
Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil.
2004 Nov
[Modern aproaches to the treatment of early stages of Parkinson disease].
2005
End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
2005 Jul
Chemically modified carbon paste electrode for the potentiometric flow injection analysis of piribedil in pharmaceutical preparation and urine.
2005 Jul 15
[The role of pronoran in the therapy of late stage of Parkinson's disease].
2006
Restless legs syndrome: diagnosis and review of management options.
2006 Jun
[Cognitive disturbances and dysfunction of neuromediator systems in cerebral vascular insufficiency after treatment with pronoran].
2007
Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.
2007 Apr
Impaired cognition and attention in adults: pharmacological management strategies.
2007 Feb
Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency.
2007 Jan 30
[Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
2008
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
2008
Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
2008 Aug
Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents.
2008 Jul
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.
2008 Sep
Ruthenium-catalyzed N-alkylation of amines and sulfonamides using borrowing hydrogen methodology.
2009 Feb 11
Hallucinations: Etiology and clinical implications.
2009 Jul
Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
2010 Feb 15
Cognitive psychiatry in India.
2010 Jan
Impulse control disorder and piribedil: report of 5 cases.
2010 Jan-Feb
From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
2010 Nov
Patents

Patents

Sample Use Guides

For the treatment of Parkinson's disease as a monotherapy, piribedil should be administered orally at 150 to 250 mg.
Route of Administration: Oral
Binding of piribedil to D2, D3 and D4 receptors was measured using [3H]spiperone as a radiolabel. Coronal sections from rat brains were cut at the level of the anterior caudate-putame. The sections were thaw-mounted on gelatin-coated glass slides. Sections were incubated for 5 min in a 50mM Tris-HCl buffer, then were incubated for 30 min at room temperature in the incubation buffer. Piribedil was tested in vitro at 5 different concentrations, from 10 uM to 1 nM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:28:07 UTC 2021
Edited
by admin
on Sat Jun 26 06:28:07 UTC 2021
Record UNII
DO22K1PRDJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIRIBEDIL
INN   MART.   MI   WHO-DD  
INN  
Official Name English
PIRIBEDIL [INN]
Common Name English
EU-4200
Code English
PIRIBEDIL [WHO-DD]
Common Name English
2-(4-PIPERONYL-1-PIPERAZINYL)PYRIMIDINE
Systematic Name English
TRIVASTAL
Brand Name English
ET-495
Code English
PIRIBEDIL [MI]
Common Name English
PIRIBEDIL [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC N04BC08
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
WHO-VATC QN04BC08
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
NCI_THESAURUS C66884
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
Code System Code Type Description
DRUG BANK
DB12478
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
MESH
D010891
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
RXCUI
8353
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY RxNorm
FDA UNII
DO22K1PRDJ
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
NCI_THESAURUS
C81082
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
MERCK INDEX
M8877
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
222-764-6
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
WIKIPEDIA
PIRIBEDIL
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
ChEMBL
CHEMBL1371770
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
CAS
3605-01-4
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
INN
2569
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
EPA CompTox
3605-01-4
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
PUBCHEM
4850
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
DRUG CENTRAL
2202
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
EVMPD
SUB09908MIG
Created by admin on Sat Jun 26 06:28:07 UTC 2021 , Edited by admin on Sat Jun 26 06:28:07 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY